



CIN NO.: L24230WB1982PLC034492

Date: 10<sup>th</sup> November, 2020

To,  
The Secretary,  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range,  
Kolkata – 700 001

Dear Sir,

**Sub: Outcome of Board Meeting held on 10<sup>th</sup> November, 2020**

This is to inform you that, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board of Director at its meeting was held at its Registered Office on Tuesday, 10<sup>th</sup> November, 2020 (**commenced at 01:30 P.M. and concluded at 02:20 P.M.**) have inter-alia considered, approved and adopted the following agenda:

1. Standalone Unaudited Financial Results of the Company for the 02<sup>nd</sup> quarter ended 30<sup>th</sup> September, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Limited Review Report by the Statutory Auditors on Standalone Unaudited Financial Results for 02<sup>nd</sup> quarter ended 30<sup>th</sup> September, 2020.
3. Appointment of M/s. Kumar Roybarman Prasanta and Associates (FRN: 330634E), Chartered Accountants, Kolkata as Internal Auditor of the Company for the Financial Year 2020-2021 pursuant to Section 138 of the Companies Act, 2013.
4. Appointment of M/s. Veenit Pal & Associates, Company Secretary, Mumbai as Secretarial Auditors of the Company for the Financial Year 2020-2021 pursuant to Section 204 to conduct Secretarial Audit of the Company.
5. The resignation letter tendered by Mr. Ganga Sahai (DIN: 07116838) from the post of Directorship with effect from 10/11/2020 after conclusion of this Board Meeting due to his personal reasons. The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015 is as enclosed herewith.

Further, the Company has received confirmation from Mr. Ganga Sahai (DIN: 07116838) stating that there are no other material reasons for his resignation other than those which are provided in the resignation letter dated November 05, 2020. The said aforesaid confirmation is also enclosed herewith.

Email: [investors@adinathbio.com](mailto:investors@adinathbio.com)  
Website: [www.adinathbio.com](http://www.adinathbio.com)

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone: +91-33-22315718

6. Board of Directors of the Company has been reconstituted the Committees of the Board. The following is the new composition of the Board members and committees:

**Board of Directors**

Sr. No.	Name of Director	Category
1.	Mr. Kishan Singh	Whole Time Director
2.	Mrs. Sharmila Ranabhat	Non-Executive Independent Director / Women Director
3.	Mr. Shri Prakash	Non-Executive Independent Director
4.	Mr. Manoj Kumar	Non-Executive Independent Director
5.	Mr. Vivek Rana	Chief Financial Officer
6.	Ms. Yamini Guleria	Company Secretary & Compliance Officer

**Audit Committee**

Sr. No.	Name of Director	Category
1.	Mrs. Sharmila Ranabhat	Non-Executive Independent Director/Women Director /Member
2.	Mr. Shri Prakash	Non-Executive Independent Director /Chairman
3.	Mr. Manoj Kumar	Non-Executive Independent Director /Member

**Nomination and Remuneration Committee**

Sr. No.	Name of Director	Category
1.	Mrs. Sharmila Ranabhat	Non-Executive Independent Director/Women Director /Member
2.	Mr. Shri Prakash	Non-Executive Independent Director /Chairman
3.	Mr. Manoj Kumar	Non-Executive Independent Director /Member

**Stakeholders and Relationship Committee:**

Sr. No.	Name of Director	Category
1.	Mrs. Sharmila Ranabhat	Non-Executive Independent Director/Women Director /Member
2.	Mr. Shri Prakash	Non-Executive Independent Director /Chairman
3.	Mr. Manoj Kumar	Non-Executive Independent Director /Member

**Risk Management Committee:**

Sr. No.	Name of Director	Category
1.	Mrs. Sharmila Ranabhat	Non-Executive Independent Director/Women Director /Member
2.	Mr. Shri Prakash	Non-Executive Independent Director /Chairman
3.	Mr. Manoj Kumar	Non-Executive Independent Director /Member

7. The undertaking of non-applicability of Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is enclosed herewith.

Email:investors@adinathbio.com  
 Website:www.adinathbio.com

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
 Telephone:+91-33-22315718



CIN NO.: L24230WB1982PLC034492

This information is also available on Company's website: [www.adinathbio.com](http://www.adinathbio.com) and on the stock exchange website: [www.cse-india.com](http://www.cse-india.com).

The Company would be publishing Extract of Unaudited Financial Result for the 02<sup>nd</sup> Quarter ended 30-09-2020, in accordance with Regulation 47(1) (b) of the Listing Regulation.

Request you to kindly take the above on record.

Thanking you,  
Yours faithfully,  
**For Adinath Bio-Labs Limited**

**Kishan Singh**  
**(Whole-Time Director)**  
**(DIN: 07526266)**  
Encl.: As above.

Email: [investors@adinathbio.com](mailto:investors@adinathbio.com)  
Website: [www.adinathbio.com](http://www.adinathbio.com)

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone: +91 -33-22315718

Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2020							
PART I						(Amount in Rs.)	
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		(30/09/2020)	(30/06/2020)	(30/09/2019)	(30/09/2020)	(30/09/2019)	(31/03/2020)
1	<b>Income from operations</b>						
	(a) Net Sales / income from operations	-	-	-	-	-	-
	(b) Other Income	63,770	63,077	63,596	126,847	126,500	253,000
	<b>Total income from operations (net)</b>	<b>63,770</b>	<b>63,077</b>	<b>63,596</b>	<b>126,847</b>	<b>126,500</b>	<b>253,000</b>
2	<b>Expenses</b>						
	(a) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-	-	-	-	-	-
	(b) Employee benefits expense	136,235	136,054	114,783	272,289	257,016	529,506
	(c) Finance Cost	-	-	-	-	-	-
	(d) Depreciation and amortisation expense	6,161	6,161	13,394	12,322	26,788	53,576
	(e) Other expenses	88,044	258,479	117,801	346,523	378,869	4,772,554
	<b>Total expenses</b>	<b>230,440</b>	<b>400,694</b>	<b>245,978</b>	<b>631,134</b>	<b>662,673</b>	<b>5,355,636</b>
3	<b>Profit / (Loss) from operations before Exceptional &amp; Extraordinary Items (1-2)</b>	<b>(166,670)</b>	<b>(337,617)</b>	<b>(182,382)</b>	<b>(504,287)</b>	<b>(536,173)</b>	<b>(5,102,636)</b>
4	Exceptional & Extraordinary Items	4,870,000	6,000,000	13,472,226	10,870,000	19,497,226	29,107,012
5	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(5,036,670)</b>	<b>(6,337,617)</b>	<b>(13,654,608)</b>	<b>(11,374,287)</b>	<b>(20,033,399)</b>	<b>(34,209,648)</b>
6	<b>Tax expense</b>						
	Current Tax	-	-	-	-	-	-
	Deferred Tax	-	-	-	-	-	-
	Earlier Years	-	-	-	-	-	-
	<b>Total Tax Expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
7	<b>Net Profit/(Loss) after tax (5 ± 6)</b>	<b>(5,036,670)</b>	<b>(6,337,617)</b>	<b>(13,654,608)</b>	<b>(11,374,287)</b>	<b>(20,033,399)</b>	<b>(34,209,648)</b>
8	<b>Other Comprehensive Income / (Loss)</b>						
9	<b>Total Comprehensive Income / (Loss) (7 ± 8)</b>	<b>(5,036,670)</b>	<b>(6,337,617)</b>	<b>(13,654,608)</b>	<b>(11,374,287)</b>	<b>(20,033,399)</b>	<b>(34,209,648)</b>
10	<b>Paid-up equity share capital (Face Value in Re.)</b>	<b>220,742,560</b>	<b>220,742,560</b>	<b>220,742,560</b>	<b>220,742,560</b>	<b>220,742,560</b>	<b>220,742,560</b>
11	<b>Earnings Per Share (Not annulised except for year ended)</b>						
	Basic & Diluted	(0.02)	(0.03)	(0.06)	(0.05)	(0.09)	(0.15)




Email: [investors@adinathbio.com](mailto:investors@adinathbio.com)  
Website: [www.adinathbio.com](http://www.adinathbio.com)

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone: +91-33-22315718

**Statement of Assets and Liabilities as on 30th September, 2020**

(Amount in Rs.)


Sl. No.	Particulars	As at 30th September, 2020	As at 31st March, 2020
		Unaudited	Audited
<b>I</b>	<b>ASSETS</b>		
<b>A</b>	<b>Non-current assets</b>		
	a) Property, plant and equipment	158,444	170,766
	b) Financial assets		
	i) Investments	287,500	287,500
	ii) Other Non current financial assets	20,187,555	31,060,317
	<b>Total Non-current assets</b>	<b>20,633,499</b>	<b>31,518,583</b>
<b>B</b>	<b>Current assets</b>		
	a) Financial assets		
	i) Trade Receivables	-	-
	ii) Cash and cash equivalents	138,603	237,610
	iii) Loans	2,530,000	2,530,000
	iv) Other current financial assets	806,333	1,073,377
	<b>Total Current assets</b>	<b>3,474,936</b>	<b>3,840,987</b>
	<b>TOTAL ASSETS</b>	<b>24,108,435</b>	<b>35,359,570</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
<b>A</b>	<b>EQUITY</b>		
	a) Equity Share capital	220,742,560	220,742,560
	b) Other Equity	(205,324,298)	(193,950,011)
	<b>Total equity</b>	<b>15,418,262</b>	<b>26,792,549</b>
<b>B</b>	<b>LIABILITIES</b>		
<b>I</b>	<b>Non-current liabilities</b>		
	(a) Deferred tax liabilities (net)	-	-
	<b>Total Non-current liabilities</b>	<b>-</b>	<b>-</b>
<b>II</b>	<b>Current liabilities</b>		
	a) Financial liabilities		
	b) Other current liabilities	242,858	119,706
	c) Current tax liabilities	8,447,315	8,447,315
	<b>Total Current liabilities</b>	<b>8,690,173</b>	<b>8,567,021</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>24,108,435</b>	<b>35,359,570</b>



Email:investors@adinathbio.com  
Website:www.adinathbio.com

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone:+91-33-22315718

<b>CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER 2020</b>		
<b>(Amount in Rs.)</b>		
<b>Particulars</b>	<b>For the Half Year Ended 30th September, 2020</b>	<b>For the Year Ended 31st March, 2020</b>
<b>(A) Cash Flow From Operating Activities</b>		
Net Profit before Tax & Exceptional items	(504,287)	(5,102,636)
<b>Adjustments for ::-</b>		
Provision for diminution in value of investments	-	-
Provision for doubtful debts	-	4,014,221
Fixed Assets Written off	-	-
Other Income	(126,847)	(253,000)
Depreciation and Amortisation on tangible assets	12,322	53,576
<b>Operating Profit Before Working Capital Changes</b>	<b>(618,812)</b>	<b>(1,287,839)</b>
<b>Adjustments for ::-</b>		
<b>Working/ Operating Capital Changes</b>		
(Increase)/ Decrease in Other Receivables	269,806	1,055,331
Increase/ (Decrease) in Other Current Liabilities	123,152	(21,689)
<b>Cash Generated From Operations</b>	<b>(225,854)</b>	<b>(254,197)</b>
Payment of Taxes	-	-
<b>Net Cash Flow (Used in)/ Generated From Operating Activities (A)</b>	<b>(225,854)</b>	<b>(254,197)</b>
<b>(B) Cash Flow From Investing Activities</b>		
Receipt/ (Repayment) of loan and advances	-	-
Interest (Net)	126,847	253,000
<b>Net Cash Flow (Used in)/ Generated From Investing Activities (B)</b>	<b>126,847</b>	<b>253,000</b>
<b>(C) Cash Flow From Financing Activities</b>		
<b>Net Cash Flow (Used in)/ Generated From Financing Activities (C)</b>	-	-
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(99,007)</b>	<b>(1,197)</b>
<b>Cash &amp; Cash Equivalents as at the beginning of the year</b>	<b>237,610</b>	<b>238,807</b>
<b>Cash &amp; Cash Equivalents as at the end of the year</b>	<b>138,603</b>	<b>237,610</b>




Email:investors@adinathbio.com  
 Website:www.adinathbio.com

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
 Telephone:+91-33-22315718

**Notes:**

- 1 The above Unaudited Financial results have been reviewed by the Audit committee at their meeting held on 10th November, 2020 and adopted by the Board of Directors at their meeting held on 10th November, 2020.
- 2 The results are based on the financial statements prepared by the Company's management in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.
- 3 The company is engaged in the business of Trading and therefore has only one reportable segment as envisaged by Ind AS 108 'Operating Segment'.
- 4 The Statutory Auditors of the Company have conducted a limited review of the above unaudited standalone financial results of the Company for the quarter and half year ended September 30, 2020 and issued an unqualified report in this behalf.
- 5 Provisions for income tax and deferred tax will be made at the end of the year except for those which pertains to earlier years on account of any specific order received by the company.
- 6 The accumulated losses have eroded net worth to the extent of 50% of the capital of the Company.
- 7 An amount of Rs.48.70 lacs have been provided and charged to profit and loss account under exceptional items on account of provision for doubtful receivables for the quarter ended 30th September, 2020.
- 8 The full impact of COVID-19 still remains uncertain and could be different from our estimates when we prepared these financial results. The Company will continue to closely monitor any material changes to future economic conditions.
- 9 Previous period's figures have been regrouped / reclassified wherever necessary to correspond with the current period's classification / disclosure.

By order of the Board  
For Adinath Bio-Labs Limited



Kishan Singh  
Whole Time Director  
DIN :07526266

Date: 10th November, 2020  
Place: Kolkata

Email: [investors@adinathbio.com](mailto:investors@adinathbio.com)  
Website: [www.adinathbio.com](http://www.adinathbio.com)

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone: +91-33-22315718

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
The Board of Directors  
Adinath Bio-Labs Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Adinath Bio-Labs Limited** (the "Company") for the quarter and half year ended on 30<sup>th</sup> September, 2020 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').


This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KSA & Co.  
Chartered Accountants  
FRN: 003822C

Rasmi Raman Jati  
Partner  
Membership No.: 511397  
Place: Delhi  
Date: 10/11/2020  
UDIN: 20511397AAAAEF9576




**Delhi:** K-8, Ground Floor, Jangpura Extension, New Delhi-110014  
Phone: +91 11 24323155, Mobile: +91 9811061238, Fax: +91 11 24323156  
**Gurgaon:** B-502, Suncity Heights, Suncity, Sector-54, Gurgaon-122001, Ph: +91 124 4241192  
**Surat:** 206, Center Point, Ring Road, Surat-395002, Ph: +91 261 2462268, +91 261 2707175  
Email: [kamalpiyush@ksaindia.in](mailto:kamalpiyush@ksaindia.in), [ksaindia.in@gmail.com](mailto:ksaindia.in@gmail.com), Website: [www.ksaindia.in](http://www.ksaindia.in)



## Resignation of Mr. Ganga Sahai (DIN: 07116838) from the Board of Adinath Biolabs Limited

Sr. No.	Details of events the need to be provided	Information of such event(s)
1	Reason for change viz. <del>appointment, resignation, removal, death or otherwise;</del>	Resignation due to personal reason  Mr. Ganga Sahai has been associated with the company since 02 <sup>nd</sup> December, 2017.  Mr. Ganga Sahai has expressed his intention to resign as an Independent Director of the Company w.e.f. 10/11/2020 after conclusion of Board Meeting.
2	Date of Appointment/cessation (as applicable)	w.e.f. 10 <sup>th</sup> November, 2020
3	Brief Profile (in case of appointment)	NA
4	Disclosure of relationship between directors (in case of appointment of director)	NA



From  
**GANGA SAHAI**  
H. No. F -125-A, Near Old Shiv Mandir,  
Gazipur Village, Delhi East,  
Delhi -110096

Date: 05/11/2020

To  
Board of Directors  
**Adinath Biolabs Limited**  
4, N. S. Road, 01<sup>st</sup> Floor,  
Kolkata - 700 001

**Sub: Resignation from the post of Director**

Dear Sir,


I, Ganga Sahai, R/o H. No. F -125-A, Near Old Shiv Mandir, Gazipur Village, Delhi East, Delhi -110096 due to personal and unavoidable circumstances. I hereby tender my resignation from the Directorship of the Adinath Biolabs Limited with effect from 10/11/2020 after conclusion of Board meeting of the Company and relieve me from my duties.

I further state that there are no other material reasons other than those provided above as a reason for my resignation from the post of Independent Director of the Company before the expiry of my tenure.

Kindly acknowledge the receipts of this resignation letter and arrange to submit the necessary forms with the Office of the Registrar of Companies, to that effect.

Thanking You,

Yours Faithfully,



**GANGA SAHAI**  
**DIN: 07116838**



CIN NO.: L24230WB1982PLC034492

Date: 10<sup>th</sup> November, 2020

To,  
The Secretary,  
**The Calcutta Stock Exchange Limited**  
7, Lyons Range,  
Kolkata – 700 001

Dear Sir,

**Sub: Non- applicability of Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) on a quarterly basis for public issue, rights issue, preferential issue etc..-

- (a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;
- (b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, Mr. Kishan Singh, Whole Time Director of Adinath Biolabs Limited hereby certify that Compliances of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable to the company, as the company has not issued any share by way of public issue, right issue, preferential issue etc. during the quarter ended on 30<sup>th</sup> September, 2020.

You are requested to take the above information in your records.

Thanking you,  
Yours faithfully,

**For Adinath Bio-Labs Limited**

**Kishan Singh**  
**(Whole-Time Director)**  
**DIN: 07526266**

Email:investors@adinathbio.com  
Website:www.adinathbio.com

4, Netaji Subhas Road, 1<sup>st</sup> Floor, Kolkata – 700 001  
Telephone:+91-33-22315718